For more information on Quantum BioPharma, please visit the company’s website at www.quantumbiopharma.com or contact the company directly at 416-555-1234.
This press release contains forward-looking statements that are based on the Company’s current expectations and beliefs. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, market conditions, regulatory approvals, and the success of the Company’s research and development efforts. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investors are cautioned that trading in securities of the Company should be considered highly speculative and involve a high degree of risk. The Company’s securities are listed on the NASDAQ, CSE, and FSE exchanges, and investors should carefully consider the investment objectives, risks, charges, and expenses before investing. Before making any investment decision, investors should consult with their financial advisor to ensure that the investment is suitable for their individual financial situation.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. The securities mentioned in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
###
For further information, please contact:
Investor Relations
Quantum BioPharma Ltd.
Email: [email protected]
Phone: 416-555-1234
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/12345″